España
India
Italia
대한민국
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Ensysce Biosciences
ENSCW
OTC
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.0310
0.00700
29.17%
Pre-Market: Aug 28, 9:14 AM EDT
Get Report
Comment
Ensysce Biosciences (ENSCW) Forecast
News
Earnings
Ensysce Biosciences (ENSCW) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Ensysce Biosciences (OTC:ENSCW) Stock
Ensysce Biosciences Stock (OTC: ENSCW)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, October 24, 2023
Ensysce Biosciences Secures $1.7M Convertible Note Financing
Happy Mohamed
Monday, December 19, 2022
Ensysce Biosciences Announces Data From PF614...
Benzinga Newsdesk
Monday, December 05, 2022
Ensysce Biosciences Announces Completion Of C...
Benzinga Newsdesk
Monday, November 14, 2022
Ensysce Biosciences Announces FDA Guidance On...
Benzinga Newsdesk
Monday, October 31, 2022
Ensysce Biosciences Announces Topline Results...
Benzinga Newsdesk
Friday, October 28, 2022
Ensysce Biosciences Announces First Subjects ...
Benzinga Newsdesk
Thursday, September 22, 2022
Ensysce Biosciences Announces Initiation Of S...
Benzinga Newsdesk
Thursday, September 08, 2022
Ensysce Biosciences Announces Results of Spec...
Benzinga Newsdesk
Wednesday, August 31, 2022
Ensysce Biosciences And Quotient Sciences Ann...
Benzinga Newsdesk
Wednesday, July 13, 2022
Ensysce Biosciences Announces Initial Patients Dosed Of First Human Abuse Potential Study
Bill Haddad
Ensysce Biosciences Announces Initial Patients Dosed Of First Human Abuse Potential Study
Bill Haddad
Monday, May 23, 2022
Ensysce Biosciences Announces Initiation Of F...
Benzinga Newsdesk
Thursday, May 05, 2022
Ensysce Biosciences Announces New Clinical Re...
Benzinga Newsdesk
Monday, January 10, 2022
Ensysce Biosciences Announces First Cohort Do...
Benzinga Newsdesk
Tuesday, January 04, 2022
Ensysce Biosciences Reports Achieved Successf...
Benzinga Newsdesk
Wednesday, December 15, 2021
Ensysce Biosciences Announces First Patients ...
Benzinga Newsdesk
Tuesday, November 30, 2021
Ensysce Biosciences Announces Clinical Trial ...
Benzinga Newsdesk
Thursday, August 05, 2021
Ensysce Biosciences Highlights Notice Of Allo...
Benzinga Newsdesk
Thursday, July 01, 2021
Ensysce Biosciences To Begin Trading On Nasda...
Benzinga Newsdesk
